Christopher Anzalone - 23 Dec 2021 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Executive Officer, Director
Signature
/s/ Christopher Anzalone
Issuer symbol
ARWR
Transactions as of
23 Dec 2021
Transactions value $
$61,273
Form type
4
Filing time
23 Dec 2021, 20:52:14
Previous filing
17 Dec 2021
Next filing
04 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Options Exercise $61.3K +11.8K +0.37% $5.19* 3.25M 23 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARWR Stock Option (right to buy Common Stock) Options Exercise $0 -11.8K -1.5% $0.00 773K 23 Dec 2021 Common Stock 11.8K $5.19 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes a total of 1,400,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole
F2 Represents first vesting date. Option vested over four years from date of grant.